This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Astrazeneca Ab. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Lucas Morrill: Innovator in Cancer Treatment
Introduction
Lucas Morrill is a notable inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of pharmaceutical compounds.
Latest Patents
Morrill holds a patent for "Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer." This patent discloses certain substituted pyrazine-2-carboxamides of Formula (I), along with their pharmaceutically acceptable salts. The compounds are recognized as inhibitors of hematopoietic progenitor kinase 1 (HPK1), making them particularly useful in the treatment or prophylaxis of cancer. He has 1 patent to his name.
Career Highlights
Lucas Morrill is currently employed at AstraZeneca AB, a leading global biopharmaceutical company. His work focuses on developing innovative therapies that address critical health challenges, particularly in oncology.
Collaborations
Morrill has collaborated with esteemed colleagues, including Sten Nilsson-Lill and Kathryn Giblin, to advance his research and enhance the impact of his inventions.
Conclusion
Lucas Morrill's contributions to cancer treatment through his patented innovations highlight his dedication to improving patient outcomes. His work exemplifies the vital role of inventors in the pharmaceutical industry.